CopyMark Law Group
4.9/5
Drawing for DAYRISE

USPTO serial 50140597

DAYRISE

Reviewed by CopyMark Law Group

Status 630
Filing date
Status date
Registration date
—
Examiner
—
Law office
—

What this means

Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.

Status 630: Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies.

Need help with DAYRISE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Joshua S. Jarvis, Esq.

Joshua S. Jarvis, Esq. Foley Hoag LLP155 Seaport BoulevardSeaport WestBoston, MA 02210-2600

Goods and services

ClassDescriptionStatusFirst use
042Conducting clinical trials for others in the field of pharmaceuticals for the treatment of facioscapulohumeral muscular dystrophy (FSHD); providing medical and scientific research information in the field of clinical trials for pharmaceuticals for the treatment of facioscapulohumeral muscular dystrophy (FSHD); providing medical research information in the field of pharmaceuticals for the treatment of facioscapulohumeral muscular dystrophy (FSHD); providing scientific research information in the field of pharmaceuticals for the treatment of facioscapulohumeral muscular dystrophy (FSHD)ACTIVE—
044Providing medical information in the field of facioscapulohumeral muscular dystrophy (FSHD); Providing medical information in the field of pharmaceuticals for the treatment of facioscapulohumeral muscular dystrophy (FSHD)ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 1, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 1, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance